171 related articles for article (PubMed ID: 17765221)
1. Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor.
Barbier AJ; Aluisio L; Lord B; Qu Y; Wilson SJ; Boggs JD; Bonaventure P; Miller K; Fraser I; Dvorak L; Pudiak C; Dugovic C; Shelton J; Mazur C; Letavic MA; Carruthers NI; Lovenberg TW
Eur J Pharmacol; 2007 Dec; 576(1-3):43-54. PubMed ID: 17765221
[TBL] [Abstract][Full Text] [Related]
2. Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors.
Letavic MA; Keith JM; Jablonowski JA; Stocking EM; Gomez LA; Ly KS; Miller JM; Barbier AJ; Bonaventure P; Boggs JD; Wilson SJ; Miller KL; Lord B; McAllister HM; Tognarelli DJ; Wu J; Abad MC; Schubert C; Lovenberg TW; Carruthers NI
Bioorg Med Chem Lett; 2007 Feb; 17(4):1047-51. PubMed ID: 17127059
[TBL] [Abstract][Full Text] [Related]
3. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist.
Barbier AJ; Berridge C; Dugovic C; Laposky AD; Wilson SJ; Boggs J; Aluisio L; Lord B; Mazur C; Pudiak CM; Langlois X; Xiao W; Apodaca R; Carruthers NI; Lovenberg TW
Br J Pharmacol; 2004 Nov; 143(5):649-61. PubMed ID: 15466448
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor.
Aluisio L; Lord B; Barbier AJ; Fraser IC; Wilson SJ; Boggs J; Dvorak LK; Letavic MA; Maryanoff BE; Carruthers NI; Bonaventure P; Lovenberg TW
Eur J Pharmacol; 2008 Jun; 587(1-3):141-6. PubMed ID: 18499098
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
[TBL] [Abstract][Full Text] [Related]
6. A Novel Potent and Selective Histamine H
Hino N; Marumo T; Kotani M; Shimazaki T; Kaku-Fukumoto A; Hikichi H; Karasawa JI; Tomishima Y; Komiyama H; Tatsuda E; Nozawa D; Nakamura T; Chaki S
J Pharmacol Exp Ther; 2020 Nov; 375(2):276-285. PubMed ID: 32862143
[TBL] [Abstract][Full Text] [Related]
7. Exploration of structure-activity relationships for dual serotonin transporter reuptake inhibitors-histamine H3 receptor antagonists.
Stocking EM; Letavic MA; Bonaventure P; Carruthers NI
Curr Top Med Chem; 2010; 10(5):596-616. PubMed ID: 20166942
[TBL] [Abstract][Full Text] [Related]
8. Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130.
Taber MT; Wright RN; Molski TF; Clarke WJ; Brassil PJ; Denhart DJ; Mattson RJ; Lodge NJ
Pharmacol Biochem Behav; 2005 Mar; 80(3):521-8. PubMed ID: 15740795
[TBL] [Abstract][Full Text] [Related]
9. JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition.
Galici R; Boggs JD; Aluisio L; Fraser IC; Bonaventure P; Lord B; Lovenberg TW
Neuropharmacology; 2009 Jun; 56(8):1131-7. PubMed ID: 19345233
[TBL] [Abstract][Full Text] [Related]
10. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
Brennan JA; Graf R; Grauer SM; Navarra RL; Pulicicchio CM; Hughes ZA; Lin Q; Wantuch C; Rosenzweig-Lipson S; Pruthi F; Lai M; Smith D; Goutier W; van de Neut M; Robichaud AJ; Rotella D; Feenstra RW; Kruse C; Broqua P; Beyer CE; McCreary AC; Pausch MH; Marquis KL
J Pharmacol Exp Ther; 2010 Jan; 332(1):190-201. PubMed ID: 19828876
[TBL] [Abstract][Full Text] [Related]
11. Clobenpropit, a histamine H
Mena-Avila E; Márquez-Gómez R; Aquino-Miranda G; Nieto-Alamilla G; Arias-Montaño JA
Pharmacol Rep; 2018 Feb; 70(1):146-155. PubMed ID: 29414147
[TBL] [Abstract][Full Text] [Related]
12. Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors.
Keith JM; Gomez LA; Wolin RL; Barbier AJ; Wilson SJ; Boggs JD; Mazur C; Fraser IC; Lord B; Aluisio L; Lovenberg TW; Carruthers NI
Bioorg Med Chem Lett; 2007 May; 17(9):2603-7. PubMed ID: 17317177
[TBL] [Abstract][Full Text] [Related]
13. SKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activity.
Fang X; Guo L; Jia J; Jin GZ; Zhao B; Zheng YY; Li JQ; Zhang A; Zhen XC
Acta Pharmacol Sin; 2013 Sep; 34(9):1149-55. PubMed ID: 23892272
[TBL] [Abstract][Full Text] [Related]
14. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
[TBL] [Abstract][Full Text] [Related]
15. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
Dutta AK; Ghosh B; Biswas S; Reith ME
Eur J Pharmacol; 2008 Jul; 589(1-3):73-9. PubMed ID: 18561912
[TBL] [Abstract][Full Text] [Related]
16. [(3)H] citalopram binding to serotonin transporter sites in minnow brains.
Gould GG; Brooks BW; Frazer A
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):203-10. PubMed ID: 17697042
[TBL] [Abstract][Full Text] [Related]
17. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
Krief S; Berrebi-Bertrand I; Nagmar I; Giret M; Belliard S; Perrin D; Uguen M; Robert P; Lecomte JM; Schwartz JC; Finance O; Ligneau X
Pharmacol Res Perspect; 2021 Oct; 9(5):e00855. PubMed ID: 34423920
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
19. Further structure-activity relationship studies of piperidine-based monoamine transporter inhibitors: effects of piperidine ring stereochemistry on potency. Identification of norepinephrine transporter selective ligands and broad-spectrum transporter inhibitors.
He R; Kurome T; Giberson KM; Johnson KM; Kozikowski AP
J Med Chem; 2005 Dec; 48(25):7970-9. PubMed ID: 16335921
[TBL] [Abstract][Full Text] [Related]
20. Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.
Zhao Z; Zhang HT; Bootzin E; Millan MJ; O'Donnell JM
Neuropsychopharmacology; 2009 May; 34(6):1467-81. PubMed ID: 18923402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
